AbbVie to Build Two New Illinois Manufacturing Facilities
Pharmaceutical company AbbVie announced a $380 million investment to build two new manufacturing facilities in Illinois. The move signals continued corporate confidence in US-based production, particularly in high-value sectors like pharmaceuticals. The investment is part of a broader trend of companies reshoring or expanding domestic manufacturing capacity.
- The new facilities will be located at AbbVie's existing campus in North Chicago, Illinois, and will focus on manufacturing active pharmaceutical ingredients (APIs) for its pipeline of next-generation neuroscience and obesity medications. - Construction is slated to begin in the spring of 2026, with the plants expected to be fully operational by 2029, creating 300 new jobs for engineers, scientists, and manufacturing technicians. - This project is part of a larger trend of reshoring API production; in September 2025, AbbVie began construction on a separate $195 million facility in North Chicago to bring manufacturing of select immunology, oncology, and neuroscience APIs back to the U.S. from Europe and Asia. - The investment is a component of AbbVie's broader commitment to invest $100 billion in U.S. research and development and capital projects over the next decade. - The new facilities will incorporate advanced manufacturing technologies and artificial intelligence, a significant development for internal audit to consider regarding operational efficiency, data integrity, and cybersecurity risks. - This expansion follows a previous one at the same location, for which AbbVie received Economic Development for a Growing Economy (EDGE) tax credits from the state of Illinois. - AbbVie's domestic manufacturing expansion is not limited to Illinois, with recent announcements of a device manufacturing facility acquisition in Arizona and significant investments at its site in Massachusetts. - The move mirrors similar domestic investment pledges from other pharmaceutical giants, including Johnson & Johnson's $55 billion commitment and AstraZeneca's $50 billion allocation to U.S. manufacturing and R&D.
